• +1-646-491-9876
    • +91-20-67278686

    Search

    Primary Sclerosing Cholangitis-Pipeline Review H2 2017

    Primary Sclerosing Cholangitis-Pipeline Review H2 2017

    • Report Code ID: RW0001881460
    • Category Life Sciences
    • No. of Pages 91
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Primary Sclerosing Cholangitis-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis-Pipeline Review H2 2017 provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

    Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain chills diarrhea fatigue itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical and Discovery stages are 8 2 6 and 1 respectively.

    Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Primary Sclerosing Cholangitis-Overview
    Primary Sclerosing Cholangitis-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Primary Sclerosing Cholangitis-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Primary Sclerosing Cholangitis-Companies Involved in Therapeutics Development
    Acorda Therapeutics Inc
    Albireo Pharma Inc
    Allergan Plc
    Conatus Pharmaceuticals Inc
    Dr. Falk Pharma GmbH
    Gilead Sciences Inc
    iCo Therapeutics Inc.
    Intercept Pharmaceuticals Inc
    NGM Biopharmaceuticals Inc
    Sancilio & Company Inc
    Seres Therapeutics Inc
    Shenzhen HighTide Biopharmaceutical Ltd
    Shire Plc
    Sirnaomics Inc
    Primary Sclerosing Cholangitis-Drug Profiles
    A-4250-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    berberine ursodeoxycholate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bertilimumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Metabolic and Gastrointestinal Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cenicriviroc mesylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-9674-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HTD-1801-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IDN-7314-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    maralixibat chloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGM-282-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    norursodeoxycholic acid-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    obeticholic acid-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SC-404-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SC-435-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Primary Sclerosing Cholangitis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STP-705-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    timolumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Primary Sclerosing Cholangitis-Dormant Projects
    Primary Sclerosing Cholangitis-Discontinued Products
    Primary Sclerosing Cholangitis-Product Development Milestones
    Featured News & Press Releases
    Jun 26 2017 FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
    May 19 2017 Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva (obeticholic acid)
    Mar 02 2017 NICE Recommends Ocaliva (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England Wales and Northern Ireland
    Jan 05 2017 Phenex Receives $100 Million Milestone Payment From Gilead
    Aug 26 2016 Biotie BTT1023 Receives Orphan Drug Designation in the United States
    Jun 07 2016 Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies Including Bertilimumab for the Treatment of GI and Liver Diseases
    Apr 16 2016 Investigational treatment provides hope for some chronic liver disease sufferers
    Jan 07 2016 Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis
    Nov 09 2015 NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
    Nov 03 2015 Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
    Mar 31 2015 Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis
    Feb 17 2015 BTT1023 receives positive opinion for Orphan Drug Designation from COMP
    Jul 24 2014 Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
    Nov 18 2013 Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
    Sep 26 2013 Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Primary Sclerosing Cholangitis H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Acorda Therapeutics Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Albireo Pharma Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Allergan Plc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Conatus Pharmaceuticals Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Dr. Falk Pharma GmbH H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Gilead Sciences Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by iCo Therapeutics Inc. H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Intercept Pharmaceuticals Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by NGM Biopharmaceuticals Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Sancilio & Company Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Seres Therapeutics Inc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Shenzhen HighTide Biopharmaceutical Ltd H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Shire Plc H2 2017
    Primary Sclerosing Cholangitis-Pipeline by Sirnaomics Inc H2 2017
    Primary Sclerosing Cholangitis-Dormant Projects H2 2017
    Primary Sclerosing Cholangitis-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Primary Sclerosing Cholangitis H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Top 10 Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Acorda Therapeutics Inc
    Albireo Pharma Inc
    Allergan Plc
    Conatus Pharmaceuticals Inc
    Dr. Falk Pharma GmbH
    Gilead Sciences Inc
    iCo Therapeutics Inc.
    Intercept Pharmaceuticals Inc
    NGM Biopharmaceuticals Inc
    Sancilio & Company Inc
    Seres Therapeutics Inc
    Shenzhen HighTide Biopharmaceutical Ltd
    Shire Plc
    Sirnaomics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//primary-sclerosing-cholangitis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//primary-sclerosing-cholangitis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//primary-sclerosing-cholangitis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments